Biomerica (BMRA) Long-Term Deferred Tax (2011 - 2023)

Biomerica's (BMRA) quarterly Long-Term Deferred Tax came in at $8.1 million in Q1 2023, up 4.39% quarter-over-quarter from $7.7 million in Q4 2022.

Biomerica (BMRA) Long-Term Deferred Tax (2011 - 2023) Analysis & Trends

Biomerica has disclosed Long-Term Deferred Tax across 11 years of filings, most recently posting $8.1 million for Q1 2023.

  • Long-Term Deferred Tax for Q1 2023 came in at $8.1 million, changed N/A year-over-year; the trailing twelve-month figure through Feb 2023 was $8.1 million (changed N/A YoY), and the FY2022 annual result was $7.0 million, changed N/A from the prior year.
  • Long-Term Deferred Tax came in at $8.1 million for Q1 2023 at Biomerica, up from $7.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $8.1 million in Q1 2023 to a low of $10000.0 in Q1 2019.
  • The 3-year median for Long-Term Deferred Tax is $7.4 million (2022), against an average of $6.0 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 Biomerica 5.57 Mn 4.23 Mn -44,000.00

Historic Data

Download Data
DateValue
Feb 28, 2023 8.09 Mn
Nov 30, 2022 7.75 Mn
Aug 31, 2022 7.40 Mn
May 31, 2022 6.97 Mn
Feb 28, 2019 10,000.00
Nov 30, 2018 10,000.00
Aug 31, 2018 10,000.00
May 31, 2018 10,000.00
Aug 31, 2017 41,000.00
May 31, 2017 41,000.00
Feb 28, 2017 41,000.00
Nov 30, 2016 41,000.00
Aug 31, 2016 41,000.00
May 31, 2016 41,000.00
Feb 29, 2016 998,000.00
Nov 30, 2015 873,000.00
Aug 31, 2015 670,000.00
May 31, 2015 744,000.00
Feb 28, 2015 359,000.00
Nov 30, 2014 359,000.00